PKA SoftTouch's Micro-Needle Outperforms Traditional Syringe Injections in Veterinary Clinical Trials, Demonstrating Enhanced Drug Delivery and Efficiency

Selwyn, ON, May, 18, 2023 – Canadian MedTech company, PKA SoftTouch, announced the successful conclusion of veterinary clinical trials for its patented Micro-Needle at the University of Guelph, ON. The results revealed that the innovative device significantly outperforms traditional syringe injections by reducing the time to peak action in medication delivery efficiency.

Syringe technology has remained essentially unchanged for over 170 years. PKA SoftTouch's Micro-Needle revolutionizes the injection process by offering a pain-free, easy-to-use alternative that eliminates the need for sharp disposal. The device's shallow delivery process enhances drug uptake, bioavailability, and efficacy compared to conventional deep muscular syringe injections.

Approximately 16 billion syringe injections are administered worldwide yearly, with the World Health Organization (WHO) predicting a 2.0 billion needle deficiency this year. The low-cost production and rapid, safe, and pain-free delivery of medications make the PKA SoftTouch Micro-Needle an ideal solution for vaccine administration.

The Micro-Needle features a tiny hidden needle that penetrates only 1.5 mm (about 0.06 in) into the skin surface, avoiding nerves and remaining invisible to the user. The device aims to help the 27% of the population experiencing 'Trypanophobia' (needle-phobia) who avoid medical treatment due to fear of needles.

During the trials, animals responded positively to the Micro-Needle injections without expressing discomfort. Technicians quickly gained proficiency with the device thanks to its user-friendly design. Dr Pankaj Modi, PKA SoftTouch’s CEO and Micro-Needle inventor, says “the results are wonderful and as expected. With the global pandemic stretching healthcare capacity across the world and more patients requiring injections for a variety of health reasons, these trials show that we have the technology to provide better, more efficient treatment." ​

Following $1,150,000 in funding from successful equity crowdfunding campaigns hosted by FrontFundr, PKA SoftTouch will now focus on commercializing the device for the animal market and conducting human trials. The company is preparing for its next equity crowdfunding round to launch this Spring. To reflect the successful veterinary trials and progress made, the share price has increased from $0.20 to $0.50.

The Micro-Needle's profit model is based on licensing, with pharmaceutical companies set to license, manufacture, prefill, and sell the technology. Dr Modi confirmed ongoing discussions with companies expected to adopt this innovative technology.

About PKA SoftTouch:

PKA SoftTouch Corp. is a research and development company dedicated to creating unique, revolutionary, and proprietary devices such as the PKA SoftTouch Micro-Needle. The patented, prefilled Micro-Needle technology is designed for painless, safe, inexpensive, and simple medication administration for humans and animals. The device injects medication into skin layers without nerves, eliminating pain and aiming to replace traditional syringe medication delivery methods, ultimately improving the quality of life for millions of users worldwide.

Connect with PKA SoftTouch: Website | Facebook | LinkedIn | Instagram | Twitter 

For media inquiries, interviews or the full trial report, please contact:

Victoria Bennett

E: victoria@bmwconsults.com

P: +1 (403) 589-7992 | +44 0207 193-7188